How Much Weight Can You Lose on Semaglutide? Real Trial Data
Modern Weight Science Editorial Team
Editorial Team
The clinical trials show average weight loss of around 15% of body weight on Wegovy. But averages conceal wide individual variation — understanding what actually drives results is more useful than a single headline number.
The headline figure most often cited for semaglutide weight loss comes from the STEP-1 trial: participants on 2.4 mg weekly Wegovy lost an average of 14.9% of their body weight over 68 weeks. For someone starting at 220 lb (100 kg), that represents roughly 33 lb (15 kg). That is meaningful — but averages hide a great deal of individual variation that is worth understanding.
What the STEP trials actually showed
The STEP programme was the pivotal clinical trial series supporting Wegovy's approval. Key results:
- STEP-1 (adults with obesity, no diabetes): Average 14.9% body weight loss on semaglutide 2.4 mg vs. 2.4% on placebo over 68 weeks. About 1 in 3 participants lost 20% or more of their body weight.
- STEP-2 (adults with type 2 diabetes and obesity): Average 9.6% weight loss — lower than STEP-1 because type 2 diabetes is associated with reduced weight-loss response to GLP-1 medications.
- STEP-3 (semaglutide plus intensive behavioural therapy): Average 16% weight loss — the combination with structured lifestyle support improved outcomes.
- STEP-4 (continuation vs. withdrawal after 20 weeks): Patients who continued on semaglutide kept losing weight; those who switched to placebo regained the majority of what they had lost within a year. This confirmed that the drug needs to be continued to maintain results.
The distribution matters more than the average
Looking only at averages misses the full picture. In STEP-1:
- ~69% of participants lost at least 10% of body weight
- ~50% lost at least 15%
- ~32% lost at least 20%
- A minority lost less than 5% — these are called non-responders or minimal responders
This means there is a real subset of people who respond exceptionally well, and a smaller subset who do not respond meaningfully at all. There is currently no reliable way to predict in advance which category a given individual will fall into.
Factors that influence individual results
- Dose: Higher doses produce more weight loss. Patients who cannot tolerate 2.4 mg and stabilise at 1 mg will see less effect on average.
- Diabetes status: Type 2 diabetes is consistently associated with smaller weight loss response to GLP-1 medications — the underlying insulin resistance appears to moderate the effect.
- Diet and protein intake: Adequate protein intake and resistance training help preserve lean mass, which affects both the scale and body composition outcomes.
- Duration of treatment: Weight loss continues beyond 16 weeks. Most patients have not reached their maximum response by month three.
- Adherence: Consistent weekly dosing matters. Missing doses reduces cumulative exposure and effect.
How long does it take?
Weight loss on semaglutide is gradual. Most patients see:
- Weeks 1–4: Minimal scale change; the starting dose is not therapeutic
- Months 2–3: Appetite suppression clearly active; modest scale movement
- Months 3–6: The most visible phase of weight loss for many patients
- Months 6–12: Continued loss, often slowing somewhat
- 12+ months: Approaching plateau for most patients; some continue to lose slowly
What happens after stopping
The STEP-4 withdrawal data is unambiguous: most patients regain the majority of lost weight within 12 months of stopping semaglutide. This is not a sign the drug failed — it reflects that the hormonal environment driving appetite and satiety returns to its pre-treatment state. Long-term planning for maintenance is part of a complete treatment approach, not an afterthought.
Trial data reflects averages across large populations. Your individual result depends on dose, duration, biology, and behaviours. Discuss realistic expectations with your prescriber rather than benchmarking against trial averages.
About the author
Modern Weight Science Editorial Team
Editorial Team
Evidence-based research and educational content focused on metabolism, appetite regulation, and sustainable weight management. Our team synthesizes peer-reviewed research into clear, accessible guidance for informed health decisions.
Content reviewed against peer-reviewed research. Read our editorial policy →
Last updated May 2026
Frequently Asked Questions
Why do most diets fail long-term?
After diet-induced weight loss, the body mounts a sustained compensatory response: ghrelin stays elevated, leptin stays suppressed, resting metabolic rate decreases beyond mass loss, and NEAT drops automatically. The Biggest Loser follow-up study found contestants' metabolic rates remained ~500 kcal/day below prediction six years later, even as most regained significant weight. These changes work against maintenance regardless of effort.
How much weight loss is realistic on GLP-1 medications?
STEP 1 (semaglutide 2.4mg) showed 14.9% average weight loss at 68 weeks. SURMOUNT-1 (tirzepatide 15mg) showed 20.9% at 72 weeks — the highest ever recorded in a randomized pharmaceutical trial. These are means: approximately 30% of semaglutide users and 57% of high-dose tirzepatide users achieve ≥20% weight loss. Around 5-10% are non-responders.
Are GLP-1 medications more effective than diet and exercise alone?
Substantially more effective. In the STEP trials, semaglutide plus lifestyle counseling produced 14.9% weight loss versus 2.4% for lifestyle counseling alone — approximately a 6-fold difference. The key mechanism is that GLP-1 medications reduce the biological drive to eat, making caloric deficit sustainable rather than requiring constant active resistance against elevated hunger hormones.
What does long-term sustainable weight management look like?
National Weight Control Registry data from people who maintained ≥30 lbs weight loss for ≥1 year identifies consistent patterns: ~1 hour/day of physical activity, regular self-monitoring, consistent dietary patterns (including regular breakfast), and high dietary vigilance. With continued GLP-1 medication, two-year data shows ~15% weight loss maintained without significant rebound — suggesting pharmacological support may be part of a realistic long-term strategy for many people.
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.
Treatment Options
Clinically supervised approaches to metabolic health and weight management, evaluated by licensed physicians.
Ro Body
A physician-led telehealth program that evaluates your metabolic health and discusses FDA-cleared medication options where clinically appropriate.
Learn moreFound
Combines medical evaluation, pharmacotherapy when indicated, and behavioral coaching into a structured, ongoing metabolic health plan.
Learn moreCalibrate
A year-long metabolic reset built around GLP-1 medication, with physician oversight, registered dietitian support, and behavioral coaching.
Learn moreAffiliate disclosure: Modern Weight Science may earn a commission if you visit or purchase through these links, at no additional cost to you. Programs are listed for educational relevance. This is not a clinical recommendation — always consult a licensed healthcare professional before starting any treatment.
Weekly Digest
Get Evidence-Based Metabolic Health Insights Weekly
Research-backed insights on metabolism, GLP-1 science, and sustainable weight management — once a week.
Continue reading
Related articles
Set Point Theory: Does Your Body Have a Defended Weight?
The phrase "set point" is technically imprecise — researchers prefer "defended range" — but the underlying observation is well-supported. Across fifty years of starvation studies, twin research, and modern hormonal trials, bodies push back when their weight is moved.
Yo-Yo Dieting (Weight Cycling): Health Risks and How to Break the Cycle
Repeated cycles of loss and regain are independently associated with visceral fat redistribution, higher cardiovascular risk, and metabolic dysregulation — beyond the effects of obesity itself. The data make a quiet case for sustained treatment over repeated attempts.
Weight Regain After Stopping Ozempic: What the Research Actually Shows
STEP 4 randomised people who had already lost weight on semaglutide to either continue or switch to placebo. The placebo group regained two-thirds of their loss within a year — and the biology behind that pattern explains the rest.
Keto, Paleo, Intermittent Fasting — Why Popular Diets Don't Last
DIETFITS, A TO Z, PREDIMED. Long-term head-to-head diet trials reveal a stubborn pattern: at 12 months, the differences between approaches are smaller than the differences between adherent and non-adherent individuals.